Question: Who's most responsible for infant deaths?
Powered by ReadrBoard: Tell us what you think by highlighting any phrase or comment and adding your reaction.
A few things to know:
• McNeil Consumer Healthcare, the Johnson & Johnson unit that makes Tylenol, and the Food and Drug Administration both knew for 15 years about the sometimes-lethal confusion over its Tylenol products for infants and children. Drop for drop, the strength of Infant’s Tylenol used to far exceed that of Children’s Tylenol. By confusing the products and administering too much of the infant’s version, parents or caretakers could inadvertently overdose their children.
• Aware of the problem, McNeil continued to sell the products as it pleaded with the Food and Drug Administration to add a dosing label that the company believed would solve the problem. The current label instructs consumers to call a doctor to get dosing instructions for children under two — but there is ample evidence that even healthcare providers sometimes mix up the products and give the wrong dosing instructions. McNeil wanted the FDA to add specific instructions by age and weight.
As of 2011, McNeil and other acetaminophen makers voluntarily agreed to stop selling two different concentrations of pediatric products. Today, infants’ and Children’s Tylenol have the same concentration, eliminating the potential confusion between two formulations.
• The FDA, has yet to take formal action. It has not mandated a single concentration. Nor has it decided whether to implement McNeil’s suggestion to add dosing information for kids under two.
Thank you for your interest in republishing this story. You are are free to republish it so long as you do the following:
You have to credit ProPublica and any co-reporting partners. In the byline, we prefer “Author Name, Publication(s).” At the top of the text of your story, include a line that reads: “This story was originally published by ProPublica.” You must link the word “ProPublica” to the original URL of the story.
If you’re republishing online, you must link to the URL of this story on propublica.org, include all of the links from our story, including our newsletter sign up language and link, and use our PixelPing tag.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week,” and “Portland, Ore.” to “Portland” or “here.”)
You cannot republish our photographs or illustrations without specific permission. Please contact [email protected].
It’s okay to put our stories on pages with ads, but not ads specifically sold against our stories. You can’t state or imply that donations to your organization support ProPublica’s work.
You can’t sell our material separately or syndicate it. This includes publishing or syndicating our work on platforms or apps such as Apple News, Google News, etc.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually. (To inquire about syndication or licensing opportunities, contact [email protected].)
You can’t use our work to populate a website designed to improve rankings on search engines or solely to gain revenue from network-based advertisements.
We do not generally permit translation of our stories into another language.
Any website our stories appear on must include a prominent and effective way to contact you.
If you share republished stories on social media, we’d appreciate being tagged in your posts. We have official accounts for ProPublica on Twitter, Facebook and Instagram.
Copy and paste the following into your page to republish: